Table 1 Studies investigating preoperative ctDNA in patients with rectal tumors
Study population | ctDNA detection rate | Primary outcome | HR (CI); P-value | Setting | |
|---|---|---|---|---|---|
Tie et al. 2019 [3] | 159 pts, T3/4, N + LARC | 77% | RFS | 1.1 (0.42-3.0); P = 0.823 | Pre-neoadjuvant |
8.3% | 6.6 (2.6–17); P < 0.001 | Post-neoadjuvant, Preoperative | |||
Kotani D et al. 2023 [2] | 1039 pts, Stage II-IV resectable CRC | 91% | DFS | 0.89 (0.55–1.4); P = 0.620 | Preoperative |
Zhou et al. 2021 [5] | 109 pts, LARC | 75% | MFS | NA (NA); P = 0.03 | Pre-neoadjuvant |
15.6% | 6.635 (1.24–35.50); P < 0.001 | During-neoadjuvant | |||
10.5% | 19.82 (2.029–193.7); P < 0.001 | Post-neoadjuvant, Preoperative | |||
Vidal et al. 2021 [4] | 180 pts, LARC | 83% | DFS, OS | NA (NA); P = 0.59, NA (NA); P = 0.38 | Pre-neoadjuvant |
15% | 4; P = 0.033, 23; P < 0.0001 | Post-neoadjuvant, Preoperative | |||
Murahashi et al. 2020 [8] | 85 pts, LARC | 57.6% | pCR | Change in ctDNA more than 80%: 7.4 (1.2–144), P = 0.0276 | Pre-neoadjuvant |
22.3% | Post-neoadjuvant, Preoperative | ||||
Pazdirec et al. 2020 [12] | 33 pts, LARC, Stage II/III | 21.1% | DFS, OS | NA (NA); P = 0.015, NA (NA); P = 0.01 | Pre-neoadjuvant |
Roesel et al. 2022 [13] | 23 pts, LARC | 87% | pCR, Recurrence | NA (NA); P = 0.45, NA (NA); P = 0.54 | Pre-neoadjuvant |
17.4% | NA | 4 weeks post-neoadjuvant | |||
13% | NA | 7 weeks post-neoadjuvant | |||
29% | NA (NA); P = 1, NA (NA); P = 0.61 | 16 weeks post-neoadjuvant (preoperative) | |||
Khakoo et al. 2020 [1] | 47 pts, LARC | 74.4% | MFS | 2.1 (0.5–9.6); P = 0.33 | Pre-neoadjuvant |
21.3% | 2.6 (0.9–8.1); P = 0.09 | On-neoadjuvant | |||
21.3% | 7.1 (2.4–21.5); P < 0.001 | Post-neoadjuvant |